Akebia Shares Plunge 26% After CFO Appointment and Vafseo NDA Resubmission Plans

Introduction

Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 2007, Akebia focuses on developing and commercializing therapies for individuals with kidney disease. The company markets two U.S. Food and Drug Administration (FDA)–approved products—Auryxia® and Vafseo®—and is advancing a pipeline of investigational agents targeting complications associated with chronic kidney disease (CKD).

Corporate Structure

According to company-reported data and LinkedIn insights, Akebia employs between 201 and 500 professionals across research, commercial, medical affairs, manufacturing, and support functions. Its organizational model includes:

• Research and development teams advancing small molecules and late-stage clinical programs
• Commercial teams responsible for Auryxia (ferric citrate) and Vafseo (vadadustat) in key markets
• Corporate functions covering finance, regulatory affairs, and patient-support services

Kidney disease by Robina Weermeijer

Recent Developments

• June 13, 2023: Akebia announced the appointment of Ellen Snow as Senior Vice President, Chief Financial Officer, and Treasurer, effective July 17, 2023. Snow joined from Pear Therapeutics and brings experience in accounting and financial management.
• October 2025: The company disclosed five scientific presentations at the American Society of Nephrology (ASN) Kidney Week 2025, providing information on hypoxia-inducible factor activation and anemia treatment in dialysis-dependent patients.
• Regulatory Pathway: Akebia is preparing to resubmit a New Drug Application (NDA) for vadadustat (Vafseo) in the U.S., following its approval in Europe and Japan.

Financial and Strategic Analysis

As of October 29, 2025, Akebia’s trading metrics were:

• Price: $2.28 per share (intraday decline of 26.21%)
• Volume: 195,611 shares
• Fair-value estimate: $3.16 per share (Yahoo Finance model)

Strategic highlights include:

• Product portfolio: Auryxia is used for serum phosphorus control and the treatment of iron-deficiency anemia in CKD; Vafseo is approved in Europe for dialysis-dependent CKD and in Japan for both dialysis-dependent and non-dialysis-dependent CKD.
• Pipeline candidates: AKB-9090 is being evaluated for acute kidney injury following cardiac surgery and acute respiratory distress syndrome; AKB-10108 is in development for retinopathy of prematurity.
• Partnerships: Akebia has collaboration agreements with Mitsubishi Tanabe Pharma for the development and commercialization of Vafseo in Japan and select Asian markets, and with Medice for its launch in Europe.

Market Position and Industry Context

Chronic kidney disease affects nearly 37 million Americans and represents a significant medical need. Within the nephrology sector, Akebia competes alongside other biopharmaceutical firms developing hypoxia-inducible factor prolyl hydroxylase inhibitors and phosphate binders. The company’s focus on patient support through its AkebiaCares reimbursement resources, coupled with geographic expansion efforts, distinguishes its commercial strategy.

TL;DR

Akebia Therapeutics shares fell 26.21% on October 29, 2025, closing at $2.28. The company is preparing to resubmit a U.S. NDA for Vafseo following its approvals in Europe and Japan. Key upcoming activities include U.S. regulatory feedback, interim data from its AKB-9090 and AKB-10108 trials, and continued rollout of Auryxia and Vafseo across partner regions.